Management of pituitary pars intermedia dysfunction in practice: A clinical audit.
- Journal Article
- Case Reports
- Clinical Study
- Diagnosis
- Disease
- Disease Diagnosis
- Disease Management
- Disease Treatment
- Endocrine System
- Equine Health
- Geriatric Horses
- Hormones
- Horses
- Observational Study
- Pituitary Pars Intermedia Dysfunction
- Pony
- Veterinary Care
- Veterinary Medicine
- Veterinary Practice
- Veterinary Procedure
- Veterinary Research
Summary
This research study investigates how guidelines for the treatment and monitoring of pituitary pars intermedia dysfunction (PPID) in horses are followed in a real-world veterinary practice. It uncovers that while most cases receive treatment as recommended, monitoring protocols are not consistently adhered to.
About the Research
The researchers embarked on a clinical audit of veterinary practice, specifically looking at the treatment and monitoring of pituitary pars intermedia dysfunction (PPID) in horses and ponies. Their key interest was to see whether the recommended treatment and monitoring guidelines, including the use of pergolide mesylate and tracking therapeutic response, were actually being implemented in a typical veterinary setting.
Methodology
- The study involved a review of case records and plasma adrenocorticotropic hormone (ACTH) concentrations of all equids (a term that includes horses, donkeys and mules) tested for PPID between 2012 and 2016 from a single veterinary practice in the UK.
- The information extracted from these records was then compared with published recommendations on PPID treatment and monitoring.
- The final audit population, after exclusions, consisted of 480 animals.
Findings
- Out of the total audit population, 51.7% were found to test positive for PPID, 37.1% were negative and 11.3% had an equivocal or unclear result.
- Treatment with pergolide was initiated in the recommended manner in 78.7% of positive cases, 19.2% of equivocal cases, and 6.4% of negative cases.
- Only 77.7% of pergolide-treated animals had documented evidence of PPID monitoring. Even then, only 48.1% of these had a follow-up basal ACTH test within the recommended period of 1-3 months after diagnosis.
Conclusion
The results from this clinical audit show that there is a significant gap between the recommended guidelines for managing PPID in equids and what happens in practice, particularly when it comes to monitoring the animals post-treatment. This disjoint suggests that efforts need to be directed towards enhancing adherence to the complete set of guidelines in real-world veterinary practice.
Cite This Article
Publication
Researcher Affiliations
- Department of Equine Clinical Science, Faculty of Health and Life Sciences, The University of Liverpool, Leahurst, CH64 7TE Cheshire, UK.
- Department of Equine Clinical Science, Faculty of Health and Life Sciences, The University of Liverpool, Leahurst, CH64 7TE Cheshire, UK.
- Department of Equine Clinical Science, Faculty of Health and Life Sciences, The University of Liverpool, Leahurst, CH64 7TE Cheshire, UK. Electronic address: cmcgowan@liverpool.ac.uk.